Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: A population-based cohort study on treatment, toxicity and outcome

Leukemia and Lymphoma

Volumn 55, Issue 3, 2014, Pages 526-532

  Boslooper, Karin ^a   Kibbelaar, Robby ^b   Storm, Huib ^a   Veeger, Nic J G M ^c   Hovenga, Sjoerd ^b   Woolthuis, Gerhard ^d   Van Rees, Bas ^b   De Graaf, Elly ^b   Van Roon, Eric ^a   Kluin Nelemans, Hanneke C ^e   Joosten, Peter ^a   Hoogendoorn, Mels ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b Pathology Friesland ^*  (Netherlands)

^c MCL   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

DLBCL; Elderly; HemoBase; Population based

Indexed keywords

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOPLASM STAGING; PREDNISONE; REGISTRIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 84894449156     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.810737     Document Type: Article

References (39)

1. Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008;19:774-779
2. Maartense E, Kluin-Nelemans HC, Noordijk EM. Non-Hodgkin's lymphoma in the elderly. A review with emphasis on elderly patients, geriatric assessment, and future perspectives. Ann Hematol 2003;82:661-670
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242
4. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l 'Adulte. Blood 2010 ; 116 : 2040-2045
5. Pfreundschuh M, Schubert J, Ziepert M, et al. Sixversus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116
6. van de Schans SA, Wymenga AN, van Spronsen DJ, et al. Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 2012;23:1280-1286
7. HoogendoornM,JoostenP, StormH, et al.HemoBase:eenintelligent elektronisch patientendossier als coach voor de hemato-oncologische zorg. Nederlands tijdschrift voor hematologie. 2009;6:104-110
8. Swerdlow SH, Campoo E, Harris NL. WHO classification oftumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008
9. National Cancer Institute. Common Terminology Criteria for Adverse Events. NIH. 2006. Available from: http://ctep.cancer.gov/protocolDevelopment/ electronic-Applications/docs/ctcaev3.pdf
10. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007 ; 25 : 579-586
11. Maartense E Hermans J Kluin-Nelemans JC et al Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands Ann Oncol 1998 9 1219-1227
12. Peters FP, Lalisang RI, Fickers MM, et al. Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study . Ann Hematol 2001 ; 80 : 155-159
13. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003 ; 21 : 3041-3050
14. Sehn LH , Donaldson J, Chhanabhai M , et al . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005 ; 23 : 5027-5033
15. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-Arm, phase 2 trial. Lancet Oncol 2011;12:460-468
16. Morrison VA. Non-Hodgkin's lymphoma in the elderly. Part 2: treatment of diffuse aggressive lymphomas. Oncology (Williston Park) 2007;21:1191- 1198;discussion 1198-1208, 1210
17. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011 ; 47 : 8-32
18. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24: 3187-3205
19. Chrischilles E, Delgado DJ, Stolshek BS, et al. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002 ; 9 : 203-211
20. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial . Blood 2003 ; 101 : 3840-3848
21. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin' s lymphoma. J Clin Oncol 2003 ; 21 : 3041-3050
22. Cullen M , Steven N, Billingham L , et al . Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005 ; 353 : 988-998
23. Bucaneve G, MicozziA, MenichettiF, et al.Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005 ; 353 : 977-987
24. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116:5103-5110
25. Bonadio M, Morelli G, Mori S, et al. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications. Biomed Pharmacother 2005 ; 59 : 511-516
26. Mora O, Zucca E . Management of elderly patients with hematological neoplasms. Ann Oncol 2007 ; 18(Suppl. 1): i49-i53
27. Link BK, Brooks J, Wright K, et al. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma 2011; 52 : 994-1002
28. Musolino A, Boggiani D, Panebianco M, et al. Activity and safety of dose-Adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer 2011 ; 117 : 964-973
29. HainsworthJD,FlinnIW, SpigelDR, et al.Brief-durationrituximab/ chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk 2010;10:44-50
30. Walter E, Schmitt T, Dietrich S, et al. Rituximab and bendamustine in patients with CD20 + diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 2012;53:2290-2292
31. Tucci A , Ferrari S, Bottelli C, et al . A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547-4553
32. Winkelmann N, Petersen I , Kiehntopf M , et al . Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011;137:733-738
33. Aaldriks AA, Maartense E, le Cessie S, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol 2011;79:205-212
34. Caillet P, Canoui-Poitrine F, Vouriot J, et al . Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011;29:3636-3642
35. Lin TL, Kuo MC, Shih LY, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma . Ann Hematol 2012; 91 : 1383-1391
36. Kobayashi Y, Miura K, Hojo A, et al. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 2011;137: 1079-1084
37. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49:1691-1699
38. Schuurmans H, Steverink N, Lindenberg S, et al. Old or frail: what tells us more? J Gerontol A Biol Sci Med Sci 2004; 59 ; M962-M965
39. Scher KS, Hurria A . Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012 ; 30 : 2036-2038 .